Minerva Neurosciences - NERV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.00
  • Forecasted Upside: 354.55%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.42
▼ -0.08 (-3.20%)

This chart shows the closing price for NERV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Minerva Neurosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NERV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NERV

Analyst Price Target is $11.00
▲ +354.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Minerva Neurosciences in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 354.55% upside from the last price of $2.42.

This chart shows the closing price for NERV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Minerva Neurosciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/27/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$11.00N/A
8/2/2023HC WainwrightBoost TargetNeutral ➝ Neutral$8.00 ➝ $11.00Low
3/9/2023HC WainwrightReiterated RatingNeutral$8.00Low
11/10/2022HC WainwrightDowngradeBuy ➝ NeutralLow
10/20/2022HC WainwrightLower Target$8.00Low
10/17/2022JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
8/23/2022HC WainwrightLower Target$40.00 ➝ $24.00Low
3/4/2022HC WainwrightLower TargetBuy$40.00Medium
8/3/2021HC WainwrightReiterated RatingBuy$80.00Medium
6/30/2021Jefferies Financial GroupInitiated CoverageHold$24.00Medium
9/11/2020William BlairReiterated RatingHoldLow
7/2/2020HC WainwrightReiterated RatingBuy$80.00N/A
7/2/2020William BlairReiterated RatingHoldMedium
7/1/2020JMP SecuritiesReiterated RatingBuy$72.00N/A
6/8/2020HC WainwrightLower TargetBuy$160.00 ➝ $80.00Medium
6/5/2020JMP SecuritiesInitiated CoverageOutperformMedium
6/1/2020BTIG ResearchLower TargetBuy$184.00 ➝ $48.00Medium
5/29/2020HC WainwrightReiterated RatingBuy$160.00High
5/29/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$16.00High
5/29/2020William BlairDowngradeOutperform ➝ Market PerformHigh
5/14/2020BTIG ResearchInitiated CoverageBuy$184.00High
5/5/2020HC WainwrightReiterated RatingBuy$160.00Medium
2/7/2020William BlairReiterated RatingBuyLow
12/19/2019JMP SecuritiesLower TargetMarket Outperform$160.00 ➝ $144.00High
12/19/2019HC WainwrightReiterated RatingBuy$176.00 ➝ $160.00High
12/2/2019Chardan CapitalReiterated RatingBuyHigh
10/1/2019Chardan CapitalReiterated RatingBuy$136.00High
9/25/2019Chardan CapitalInitiated CoverageBuy$136.00Low
9/18/2019William BlairInitiated CoverageOutperform$208.00High
5/31/2019HC WainwrightInitiated CoverageBuy ➝ Buy$176.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/18/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/17/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/15/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Minerva Neurosciences logo
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Read More

Today's Range

Now: $2.42
Low: $2.29
High: $2.50

50 Day Range

MA: $4.57
Low: $2.42
High: $12.47

52 Week Range

Now: $2.42
Low: $2.26
High: $13.49

Volume

30,348 shs

Average Volume

110,498 shs

Market Capitalization

$16.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Minerva Neurosciences?

The following Wall Street sell-side analysts have issued stock ratings on Minerva Neurosciences in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for NERV.

What is the current price target for Minerva Neurosciences?

1 Wall Street analysts have set twelve-month price targets for Minerva Neurosciences in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 354.5%. HC Wainwright has the highest price target set, predicting NERV will reach $11.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Minerva Neurosciences in the next year.
View the latest price targets for NERV.

What is the current consensus analyst rating for Minerva Neurosciences?

Minerva Neurosciences currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NERV, but not buy more shares or sell existing shares.
View the latest ratings for NERV.

What other companies compete with Minerva Neurosciences?

How do I contact Minerva Neurosciences' investor relations team?

Minerva Neurosciences' physical mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company's listed phone number is (617) 600-7373 and its investor relations email address is [email protected]. The official website for Minerva Neurosciences is www.minervaneurosciences.com. Learn More about contacing Minerva Neurosciences investor relations.